Targeting Gene Expression to Specific Cardiovascular Cell Types in Transgenic Mice
John J. Hunter, Hong Zhu, Kevin J. Lee, Steven Kubalak, Kenneth R. Chien Transgenic techniques, which allow the introduction of exogenous genes into the genome of experimental animals, promise to bridge the gap between the in vitro observations made by molecular and cellular biologists on cardiac and vascular cells in tissue culture and the physiology and pathology of the whole organ system. One such application of these techniques is tissue targeting: by genetic manipulation to direct expression of a protein-such as a signaling peptide, a growth factor receptor, or an oncogene involved in cell growth -to a tissue where it normally would not be expressed (or where expression is tightly controlled) by fusing it to the transcriptional control sequences of another gene normally expressed in that tissue. In the cardiovascular system, regulatory sequences for cardiomyocyte-specific proteins, vascular endothelium-speciflc proteins, and smooth muscle-specific proteins can be used to target heterologous genes to their respective tissues in transgenic animals. The effects that such perturbations have on organ physiology and intraceUular and intercellular communication can be observed by applying established physiological and molecular approaches. In this review, we highlight some tissue-specific genes from cardiac and vascular cell types whose regulatory sequences may be used to target heterologous proteins; we discuss neutral "reporter" proteins and signal transduction components as paradigms for the application of this technique; and we briefly touch on the potentials and pitfalls of transgenic approaches to molecular physiology. (Hypertension. 1993^22:608-617.)
KEY WORDS • mice, transgenic • gene expression T he morphological and physiological changes in organ phenotype that accompany atherosclerosis, hypertension, cardiac hypertrophy, or heart failure are the result of a cascade of molecular, biochemical, and genetic processes that are coordinated among multiple distinct cell types. An initial understanding of these phenotypic changes has been gained from the study of the individual cellular components in culture, such as cardiac myocytes, vascular smooth muscle cells (VSMCs), interstitial fibroblasts, and vascular endothelial cells. However, given the integrative nature of the cardiovascular system, a firm picture of the individual role played by each cell type will ultimately require studies in the context of the intact animal. The difficulty has arisen in developing the means to genetically manipulate specific cell types in vivo. The development of transgenic technology holds the promise of bridging the gap between in vitro observations in cultured cells and examination of the effect of specific Received March 17, 1993 ; accepted in revised form June 14, 1993 .
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Although the eventual level of expression of a given gene is dictated by multiple regulatory steps that occur following gene transcription, control of gene transcription is one of the principal mechanisms that govern various tissue-specific gene programs. Tissue specificity appears to be conferred by specific DNA sequences (cis-acting elements) and nuclear factors that bind to these sites in a sequence-specific manner. These factors subsequently enhance or suppress transcription of a given set of genes (for a general review, see Reference 1). These tissue-specific cis-regulatory elements commonly lie in the DNA just upstream of the protein coding sequence (the 5' flanking region), although they may also reside a great distance upstream, downstream of the coding sequence (in the 3' flanking region), or within the coding sequence itself (in the first intron, for example). Each gene has a unique set of cis-acting elements, and each cell type has a limited repertoire of nuclear transcription factors; it is this interaction that determines, to a large extent, which genes are transcribed, to what level, and under what circumstances. An example would be the ventricular myosin light chain-2 (MLC 2 ») gene, a regulatory subunit of myosin that our laboratory has been studying for the past several years. This contractile protein is expressed only in heart and slow-twitch skeletal muscle, and its transcription is enhanced in response to hypertrophic stimuli, such as aortic or pulmonary artery banding in vivo or af-adrenergic stimulation in cultured heart muscle cells in vitro (for a review, see Reference 2) . Several of the important cis-acting elements within the gene that mediate cardiac specificity and inducibility have recently been identified, and an initial characterization of the nuclear transcription factors within heart muscle cells that mediate these effects has been performed (for a review, see Reference 3). Because these noncoding regulatory sequences are responsible for the restricted expression of the MLC 2v gene to cardiac and skeletal muscle, it is now possible to target coding sequences for different proteins to the heart by fusing them to those same MLC 2v regulatory sequences. The feasibility of this approach has been well demonstrated for numerous genes and organ systems by fusing the regulatory elements of a gene of interest to the coding sequence of an easily detectable "reporter" gene whose expression does not alter cellular function, such as firefly luciferase, chloramphenicol acetyltransferase (CAT), or /3-galactosidase (Fig 1) . Targeted expression of such reporter genes, in cultured cells as well as in transgenic animals, has permitted "promoter mapping," the stepwise introduction of mutations or deletions in the regulatory region in order to identify the critical cis-acting elements that mediate tissue-restricted or inducible transcription.
In a broader sense, however, one can not only target the expression of an inert reporter gene to a specific cell type but also target the expression of a protein that is biologically active (see Fig 2) . In certain cases, these transgenes might encode a dominantly active protein (such as an oncogenic mutant) or overexpress a wildtype protein in an appropriate or inappropriate cell context (ie, in cells that do not normally express the protein encoded by the transgene). In principle, one can selectively target any protein of interest to a range of organs or tissues that is determined by the specificity of the chosen promoter sequences. Inducibility by external stimuli or developmental stage specificity also can be targeted by the choice of promoter. Because genes whose expression is also regulated by alternative RNA processing or posttranslational modification present a more complex situation, which is only beginning to be explored, the current discussion will be limited to genes that are regulated predominantly at the level of transcription. Although the term "gene targeting" is used by some to denote gene replacement, which involves replacing a selected gene with a homologous but mutated copy by homologous recombination in in vitro embryonic stem cells, this review will focus on targeting transgene expression by choice of a heterologous, tissue-specific promoter.
The initial consideration of targeting gene expression in transgenic mice, then, begins with the identification of a gene whose expression is restricted to the tissue or cell type of interest, eg, expression of the cardiac MLC 2 , gene in ventricle and in slow skeletal muscle. 4 Subsequently, a DNA fragment that contains the regulatory sequences which are sufficient to confer appropriate tissue specificity must be identified; this is most commonly approached by fusing these regulatory sequences to a neutral reporter gene, such as luciferase, CAT, or /3-gaJactosidase. In the case of the MLC 2v gene, 250 bp of the promoter confers tissue specificity to a luciferase reporter, as determined by the introduction of fusion genes carrying different lengths of 5' regulatory sequence into cultured cells 3 and confirmed by in vivo expression of the fusion gene in transgenic mice. 6 Finally, one can then fuse these MLC 2 , regulatory sequences to those of the biologically active protein of interest and introduce this chimeric gene into transgenic animals, monitoring the various tissues of the progeny for the effects of tissue-targeted transgene expression.
Because the MLC-2 promoter restricts expression to the ventricular chamber of the heart, the ventricular myocardial cells can then be subjected to detailed morphological, physiological, and biochemical analysis. At this particular time, relatively few promoters have been rigorously analyzed for their ability to target expression in specific cell types in the cardiovascular system; therefore, an overview of cell type-specific proteins in the cardiovascular system will be presented to serve as a starting point for investigators in various fields of cardiovascular research. From this group of cell type-specific markers, a summary of the utility of their corresponding gene regulation sequences to confer cell specificity in tissue culture and in transgenic animals will be presented. Because the ultimate goal is to target biologically active proteins to the cardiovascular system in transgenic animals, we will briefly highlight the difficulties encountered in transgenic model systems as well as methods for determining transgene expression and assaying the potential developmental, morphological, and physiological abnormalities that may be produced.
Cardiovascular Cell Type-Specific Markers and Proteins
The cardiovascular system is composed of a wide variety of cell types, including cardiac and smooth muscle cells, endothelium, interstitial cells, and cells of the specialized conduction system. With respect to the cardiac muscle cell, each of the proteins that comprise the contractile apparatus, including myosin light and heavy chains, actin, tropomyosin, and the troponin complex constituents, have been cloned, providing a number of possibilities for achieving and monitoring cardiac muscle-specific expression (Table 1 ). However, in many cases, these myofibrillar genes are expressed in other kinds of striated muscle as well and can be subject to developmental regulation that limits their potential for directing gene expression in the adult myocardium via transgenic approaches. Likewise, the calcium-handling proteins of the sarcoplasmic reticulum (SR) are muscle specific, with additional subunit isoform specificity for cardiac or skeletal myocytes. Many of the intracellular enzymes of intermediary metabolism are ubiquitous, but a few, such as creatine kinase, exhibit striated muscle-specific isoforms. Studies of the expression of the host of ion channel proteins identified thus far make up a rapidly growing field, which should offer the potential of finding plasma membrane markers that are cell type specific. Other proteins that display tissuerestricted expression in cardiac and other tissues include atrial natriuretic factor (ANF) and, most recently, several of the nuclear transcription factors involved in regulating cardiac gene expression, such as the homeotic protein M-Hox, 73 the zinc finger protein HFlb, 74 and the myocyte enhancer factor-2 (MEF-2) family. 73 A number of tissue-restricted proteins have been identified for VSMCs and endothelial cells. Endothelium-selective proteins identified thus far include von Willebrand factor (long used as a histological marker for cells of endothelial origin, although not universally expressed 6169 ), endothelin-1, and various cell surface markers (see Table 1 ). Endothelial cells also have come under intense scrutiny as their central role in regulating vascular tone, as well as in regulating the proliferation of the underlying VSMCs, has become apparent.
Myocardial Targeting
The subsequent discussion will focus attention on those proteins whose pattern of regulatory expression (developmental, tissue-specific, and inducible) is known (see Table  2 ). Among contractile proteins, most of the recent work has focused on the cardiac myosin heavy chains (MHCs), the regulatory myosin light chain (MLC 2 v). and striated muscle actins (a-skeletal and a-cardiac). a-MHC is expressed in all cardiac chambers throughout development, 7 and the regulatory region of the a-MHC gene has been shown to confer thyroid hormone responsiveness on a CAT reporter gene in transfected cardiac cells. 76 Tissuespecific and thyroid hormone-responsive expression of the same reporter gene is conferred by the same regulatory sequences in transgenic mice. 77 0-MHC is expressed in slow-twitch skeletal muscle as well as in the heart 7 ; in rodents, its expression is downregulated after birth but is reinduced in response to pressure-overload hypertrophy or hypothyroidism. 85 In cultured cardiac ventricular myocytes stimulated by a r adrenergic agonists, an in vitro model of "hypertrophy," both 0-MHC mRNA and a CAT reporter regulated by the /J-MHC promoter are upregulated. 79 Similar to 0-MHC, M L C 2 T also is expressed in the ventricles and slow skeletal muscle in the adult and is upregulated during pressure-overload hypertrophy. During development, MLC 2 , localizes to the ventricular portion of the linear heart tube 87 and remains specific for the ventricular compartment throughout embryonic and adult development. As noted above, 250 bp of the 5' flanking region of this gene has been shown to direct cardiac-specific expression to a luciferase reporter in cultured cells/ and the same construct (as well as a transgene containing 2100 bp of 5' flanking sequence) has been shown to confer ventricular specificity in transgenic mice, 6 suggesting that elements directing skeletal muscle expression reside outside this region.
Although a-smooth muscle actin is the first actin isoform identified in the developing chick heart tube, it is subsequently replaced by the sarcomeric a-actins, a-cardiac and a-skeletal, 14 with the a-skeletal isoform declining rapidly after birth. Like other "fetal" genes, a-skeletal and a-smooth muscle actins are reexpressed in response to pressure-overload hypertrophy, 15 and the a-skeletal isoform is upregulated by a-adrenergic stimulation in cultured cardiac ventricular myocytes. 90 Transgenic mice express an a-skeletal actin-CAT fusion gene selectively in striated muscle and heart. 81 The SR calcium ATPase (SERCA), which is the principal mediator of calcium reuptake into the SR, is encoded by two genes, one for the fast skeletal isoform (SERCA1) 26 and the other generating slow skeletal/ cardiac (SERCA2) and smooth muscle isoforms by alternative transcription. 31 -32 Unlike the contractile proteins /3-MHC and MLC 2v , the SERCA2 isoform in the heart is downregulated during hypertrophy in vivo. 2830 In cultured cardiac myocytes, 3500 bp and 550 bp of 5' flanking sequence of the rat SERCA2 gene confer thyroid hormone inducibility on a CAT reporter. 48 have not yet been extensively characterized. The muscle isoform of creatine kinase has long been known to be essentially muscle specific. Although the regulatory sequences that direct expression in cultured myogenic cell lines have been well characterized, it was not until the generation of transgenic mice containing a fusion muscle creatine kinase promoter/enhancer with CAT that targeting of expression to cardiac muscle could also be demonstrated 49 (this transgenic construct will be discussed further below). ANF is a vasoactive natriuretic peptide first identified in the granules of atrial cells, from which it is released into the circulation in response to atrial distension (for reviews, see References 50 and 51). ANF is produced by ventricular myocytes in vivo in response to pressure overload, 91 volume overload, 92 or heart failure. 93 Although not entirely cardiac specific, the 5' flanking sequences of both the mouse and rat ANF genes have been shown to confer atrial-specific expression in transgenic mice. A 638-bp fragment confers inducibility to a luciferase reporter during in vitro hypertrophy of ventricular myocytes, 83 and studies are currently in progress to determine if producing pressure-overload cardiac hypertrophy in transgenic mice harboring this construct will induce luciferase activity in the ventricular myocardium.
Vascular Smooth Muscle Targeting
In addition to its role in determining arterial tone and systemic circulatory resistance, the VSMC also plays a key role in the development of atherosclerotic plaques and in restenosis after vascular interventions. VSMCs, like cardiac myocytes, contain contractile proteins consisting of hexameric myosin, actin, and tropomyosin, as well as the regulatory myosin light chain kinase and intermediate filament proteins desmin and vimentin. Characteristically, the functional, differentiated VSMC in vivo demonstrates a contractile phenotype and expresses desmin as well as vimentin, with predominantly smooth muscle-type MHC (SM-1 and SM-2 8 -9 ), MLC 1/3 (LC20), and a-smooth muscle actin. The regulation of smooth muscle MLC-2 (LC 17 ), although distinct from the nonmuscle isoform, 1112 has not been extensively studied. Development of atherosclerosis in vivo 94 or proliferating cultures of VSMCs in vitro produces a "dedifferentiated" phenotype, typically expressing lower levels of desmin, higher levels of vimentin, and a transition to nonmuscle myosins (MHC and MLC) and actins. The search for tissue-specific genes in VSMCs has been hampered by this coexpression of most genes studied in nonvascular smooth muscle cells, as well as expression of ubiquitous, nonmuscle markers by proliferative VSMCs. 95 
Vascular Endothellal Targeting
Endothelial cells express a myriad of marker genes, some of which are more or less selective for the endothelial cell type. Endothelial cells are not monomorphic, however, and the proteins they express are to some extent a function of the organ in which they are located as well as site of origin (umbilical vein versus large vessel versus microvessel). 61 Numerous monoclonal antibodies recognize endothelial markers, including CD34 and CD36, 69 but most proteins recognized are thus far unknown, 61 and the regulatory sequences of the genes that encode these proteins have not been characterized.
von Willebrand factor (vWF), an integral component of platelet adherence in the vasculature, is synthesized only by endothelial cells and megakaryocytes, 59 and anti-vWF antisera have been used for some time as a histological marker for cells of endothelial lineage. 58 The 5' regulatory region of vWF has been cloned, but efforts to express a CAT reporter under its control have been hampered by poor transfection efficiency in v\VF(+) cell lines and an inability to document use of the authentic transcription initiation site in the vWF gene. 59 Endothelin-1, a peptide initially isolated from cultured endothelial cells, is a potent constrictor of smooth muscle and stimulates growth in certain mesenchymal cell types. The 5' regulatory region of the endothelin-1 gene appears to be sufficient to direct endothelial cell-specific expression of a CAT reporter gene in vitro. 60 Cell adhesion molecules represent another class of cell type-selective molecules, and, in the endothelium, particular attention has focused on vascular cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1), PECAM-1/ CD31/ENDOCAM, and the recently described cadherin 5 ( Table 1 ). The regulatory elements from the VCAM-1 gene have been proposed as a means of targeting genes to endothelial cells, 65 although VCAM-1 is also expressed on epithelial cells as well as tissueresident leukocytes and infiltrating leukocytes during inflammation. 66 In the endothelium, VCAM-1 mRNA is induced by the inflammatory cytokines interleukin-1 and tumor necrosis factor. ELAM-1 appears to be restricted to endothelial cells 66 and, like VCAM-1, is induced by inflammatory cytokines. The 5' regulatory region of the ELAM-1 gene has been characterized, 6768 and it too has been proposed as a means of targeting gene expression to the endothelium. 65 
Cardiovascular Transgenic Model Systems
Although there have been interesting transgenic lines developed by introducing complete genes (coding and noncoding), as well as exciting developments using homologous recombination to produce gene knockouts, our discussion here will be limited to models using heterologous promoter/structural gene fusion constructs. Generation of transgenic animals by the most widely used technique, pronuclear microinjection of DNA into the fertilized oocyte, is beset by unique difficulties. These have been reviewed elsewhere, 96 but in summary, not all transgenic founders pass the transgene on to their progeny; the construct itself may be lethal in utero; and, most disturbingly, the level of transgene expression and sometimes its tissue specificity depend not only on the characteristics of the targeting promoter but also on the site of integration into the genome. For example, most transgenes discussed below are targeted for cardiovascular expression, but occasionally they represent fortuitous cardiac abnormalities resulting from unexpected expression in the heart. In a transgenic line containing a protamine promoter/simian virus 40 (SV40) T antigen chimera, designed to neoplasticalry transform haploid spermatids, the transgenic lines unexpectedly developed cardiac right atrial rhabdomyosarcomas, and some developed petrous osteosarcomas as well, although neither normal atrial and bone tissue nor the tumors themselves actually express the protamine gene. 97 Similarly, transgenic mice containing the polyomavirus large T antigen under the control of a metallothionein promoter expressed the transgene in testes, seminal vesicles, and heart of one transgenic line, but none of the lines displayed expression in the liver, kidney, brain, skeletal muscle, or stomach (where metallothionein is normally expressed). 98 One line developed severe cardiomyopathy, with premature death in 58% of the lineage. Histologically, some cardiac myocytes were markedly hypertrophied, with bizarre nuclei and positive staining for T antigen; other myocytes were normal in size, although some of these also stained positively for T antigen. Occasional areas of interstitial fibrosis were seen, but no necrotic foci were observed to suggest focal myocarditis.
As a final example of an "incidental" yet very interesting cardiac phenotype, a transgene consisting of a mouse immunoglobulin promoter, Rous sarcoma virus (RSV) long terminal repeat (LTR), and coding sequence for the c-myc proto-oncogene was found to target myc expression specifically to the heart. 99 The transgene is expressed as early as embryonic day 15 and is seen in all four cardiac chambers. The phenotype is proportional cardiomegaly deriving from accelerated hyperplasia in utero; the rate of postnatal cardiac growth remains similar to that of nontransgenic littermates (ie, there is no additional postnatal hypertrophic growth that can be ascribed to c-myc overexpression), and cardiac architecture remains normal, without tumorigenesis or a switch in a-actin isoforms. 100 Regulatory sequences from several cardiac-selective genes have been used to target expression of reporter genes or the SV40 T antigen to the heart. Three thousand three hundred nucleotides of 5' flanking sequence of the muscle creatine kinase are sufficient to direct expression of a CAT reporter to the heart as well as skeletal muscle in transgenic mice 49 ; serial deletions in this construct have allowed in vivo promoter mapping, with identification of cardiac-and skeletal muscleselective enhancers. 49 This same 3300-bp flanking sequence has been used to ectopically express the myogenic regulatory transcription factor MyoD in the heart of transgenic mice, resulting in an embryonic lethal phenotype in which aberrant expression of skeletal muscle markers is demonstrable in the heart. 101 Analogously, 191 bp of the chicken skeletal a-actin promoter is sufficient to direct cardiac-and skeletal muscle-specific expression of a CAT reporter in transgenic mice, confirming the ability of those sequences to target tissue-specific expression and the conservation of regulatory mechanisms across species lines. 81 Five hundred bp of 5' flanking sequence of the human ANF gene directs cardiac atrial-specific expression to the SV40 T antigen, with a resulting postnatal right atrial hyperplasia to 10 to 20 times the normal size; these animals ultimately develop atrial arrhythmias and die prematurely. 84 Interestingly, the left atrium expresses the T antigen without morphological changes 84 ; moreover, induction of pressure-overload hypertrophy by thoracic aortic banding in these animals did not induce ventricular T antigen expression, even though it did induce other immediate early genes and endogenous ANF itself in the ventricle, 102 further illustrating the utility of targeting transgene expression in mapping promoter elements responsible for inducibility by exogenous stimuli, as well as tissue specificity (even differentiating cardiac atria from ventricles). The 250-bp MLC 2v promoter fragment confers ventricular-specific expression to a luciferase reporter; even though the endogenous MLC 2 , is expressed in both ventricles and slow skeletal muscle, the fusion transgene was expressed only in the heart. 6 Transgenic mice generated with an a-MHC/ SV40 T antigen transgene containing 609 bp of rat a-MHC 5' flanking sequence also exhibited cardiacspecific expression of the transgene in all four chambers, as expected. 78 Despite T antigen expression in utero, it was not until birth that cardiac pathology was evident, with hyperplasia and enlargement of all chambers; ongoing DNA synthesis and cell division was demonstrable postnatally, despite the presence of sar- comeric myosin and continued contractility of isolated myocytes in vitro as differentiation markers. 78 Other structural genes of interest to the cardiovascular biologist include lipoprotein genes and their receptors, as well as components of the renin-angiotensin system; the expression of these genes has been targeted in transgenic animals by fusion with heterologous promoters. One example in the former category is the human low-density lipoprotein receptor under the control of a metallothionein promoter, which targeted overexpression of the transgene selectively to the liver. 103 Although this transgenic line had lower basal cholesterol levels than their nontransgenic counterparts, a more dramatic effect was seen when the mice were fed a high-fat, high-cholesterol diet, in which the increase in low-density lipoprotein cholesterol was abolished. In contrast to the severe hypertension produced in transgenic rats by expression of an entire mouse renin gene (regulatory and coding sequences), 10 * mice transgenic for a metallothionein-renin fusion gene did not develop hypertension, even with induction by heavy metal exposure; neither did mice expressing a metallothionein-angiotensinogen transgene, but a Mendelian cross between these two lines yielded a double transgenic line with systolic blood pressure higher than either single transgenic line, whose elevation in systolic blood pressure normalized with captopril treatment.
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Conclusions and Future Prospects
Targeting gene expression to the tissues of the cardiovascular system via transgenic approaches is now a feasible experimental tool for studying the physiology and ontogeny of specific cell types. At the present time, the optimal targeting sequences are those of genes that regulate their tissue-specific and inducible expression at the transcriptional level (characteristics of an "ideal" targeting promoter are given in Table 3 ). Among cardiac muscle genes, a-MHC, ANF, and MLC 2v already have substantial "track records" in directing cardiacspecific and, in certain cases, chamber-specific expression in transgenic mice. The 5' flanking sequences in the troponin I and cardiac a-actin genes may also confer tissue specificity. In in vitro systems, SERCA2, phospholamban, and calcium release channel genes exhibit cardiac selectivity, although these have yet to be evaluated in transgenic systems. The muscle CTeatine kinase promoter/enhancer targets the heart as well as skeletal muscle, but the regulation of other cardiac myocyte proteins such as ion channels, intermediate filaments, connexins, and adhesion molecules has not yet been characterized well enough to predict their utility in targeting expression to specific cell types in transgenic animals. Similarly, studies of the regulation of the VSMC gene program have yet to identify regulatory sequences that can target expression to this subtype of smooth muscle cell, although the smooth muscle MHCs, MLC-2, and to a lesser extent smooth muscle a-actin promoters might eventually permit targeting across all smooth muscle tissues. With respect to endothelial cells, several promising candidates for targeting expression in transgenic mice are beginning to emerge, including endothelin-1, ELAM-1, cadherin 5, the vascular endothelial growth factor receptor, and the tek tyrosine kinase genes.
The concept of tissue targeting is not new. 106 Altering the structure or function of tissues in transgenic mice by expression of heterologous genes has been used for several years to study oncogenesis, the regulation of the immune system, and growth and development (for reviews, see References 107, 108, and 109) . This review has concentrated on targeting gene expression to cardiovascular tissues; however, it is obvious that processes such as lipoprotein regulation, blood coagulation, fibrinorysis, and rheology and the function of hematogenous cells such as platelets and leukocytes are inextricably linked with function and diseases of the heart and vessels. Gene targeting to these related tissues will also affect cardiovascular function and our models of cardiac disease; this further illustrates the utility of transgenic approaches for understanding these complex interactions.
As the regulation of mammalian gene expression becomes better understood, it may become possible to construct artificial regulatory sequences, containing the recognition sites for those nuclear transcription factors whose presence and activation state actually control the expression of individual mRNAs, thus further refining our ability to target certain cell types or certain developmental or pathological stages. The tissue-specific targeting of dominantry acting proteins (either positive or negative) should open new horizons in cardiovascular biology, physiology, and medicine. By targeting the expression of proteins involved in cellular signal transduction to specific cardiovascular cell types, we not only may better understand the transduction cascade but also may identify critical targets for pharmacologic manipulation, as well as generate novel animal models of human cardiovascular disease. One can also direct synthesis of antisense RNA, which would function as a transcriptional inhibitor of expression of the endogenous "sense" mRNA; this approach has been used in transgenic mice to duplicate the "shiverer" phenotype associated with sporadic myelin basic protein deficiency by introducing an antisense myelin basic protein construct. 110 The biology of antisense RNA technology is still problematic, and despite expression of antisense RNA, the appropriate phenotype is not always obtained 111112 ; but ultimately, targeted expression of antisense or ribozyme constructs might provide a complementary approach to "gene knockout" by homologous recombination in embryonic stem cells, a technique that by nature does not permit tissue-specific, precisely targeted manipulations. Moreover, one may express certain mutant forms of cellular components that act as "dominant inhibitors" of their normal counterparts; that is, by binding and sequestering normal cofactors, they inhibit the function of the normal protein without eliminating its presence in the cell. An example would be the Ala-15 mutation in H-ras, which putativery binds to a guanine nucleotide exchange protein (an upstream activator of raj), rendering it unavailable to activate the normal ras pathway. 113 A final molecular tool that may be targeted in a cell-specific manner would be a toxin such as the A subunit of diphtheria toxin or the A subunit of ricin, whose expression within a cell results in cell death 114 ; such "genetic ablation" in the cardiovascular system would obviously require even more selective targeting than may now be envisioned.
In summary, transgenic technology is ushering in a new era of molecular physiology, an exciting, integrative discipline in which the physiological consequences of organ-specific expression of potentially interesting, biologically active molecules can be studied. The molecular mechanisms by which the heart and vessels develop and adapt to their environment can be dissected by selectively interfering with steps in the process, and novel therapeutic approaches may be discovered based on understanding these pathways (for a review, see Reference 115). Suspected genetic causes or predispositions for human diseases can be confirmed by reproducing the disease by genetic manipulation in experimental animals. Targeted gene expression using regulatory sequences that are tissue specific, developmental stage specific, and inducible in response to environmental stimuli will be a fundamental tool in this discipline, as will the ability to identify animals containing the targeted sequence, the expression of the targeted gene, and the physiological consequences of that expression. To date, the mouse has been the preferred animal for transgenic research because of knowledge of its genetic makeup and ease of genetic manipulation, and it will become imperative to develop physiological capabilities in these small animal models to assess the physiological and pathological consequences of transgene expression. In the future, we anticipate the convergence of molecular biologists, physiologists, and cardiologists at the "bedside" of mice that display cardiovascular disease phenotypes.
